Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dietmar Seiffert

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Recent Patents on Cardiovascular Drug Discovery|September 30, 2010
Challenges and promises of developing thrombin receptor antagonistsJing Yang, Ke Xu, Dietmar Seiffert
Drug Discovery Today|May 6, 2014
Inhibition of Factor XI activity as a promising antithrombotic strategyZhu Chen, Dietmar Seiffert, Brian Hawes
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Feedback activation of factor XI by thrombin does not occur in plasmaDonna L Pedicord, Dietmar Seiffert, Yuval Blat
Biochemistry|September 15, 2004
Substrate-dependent modulation of the mechanism of factor XIa inhibitionDonna L Pedicord, Dietmar Seiffert, Yuval Blat
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 30, 2005
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humansShaker A Mousa, Jeffrey M Bozarth, Dietmar Seiffert, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 9, 2007
Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonistYu Chen Barrett, William Ebling, Henry Pieniaszek, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 8, 2016
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in RabbitsXueping Zhou, Weizhen Wu, Lin Chu, et al.
Thrombosis Research|February 5, 2003
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancyJeffrey T Billheimer, Bokang He, Susan M Spitz, et al.
Clinical and Translational Science|September 24, 2021
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Joseph Luettgen, et al.
Platelets|July 3, 2023
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participantsSamira Merali, Zhaoqing Wang, Charles Frost, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Recent Patents on Cardiovascular Drug Discovery|September 30, 2010
Challenges and promises of developing thrombin receptor antagonistsJing Yang, Ke Xu, Dietmar Seiffert
Drug Discovery Today|May 6, 2014
Inhibition of Factor XI activity as a promising antithrombotic strategyZhu Chen, Dietmar Seiffert, Brian Hawes
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Feedback activation of factor XI by thrombin does not occur in plasmaDonna L Pedicord, Dietmar Seiffert, Yuval Blat
Biochemistry|September 15, 2004
Substrate-dependent modulation of the mechanism of factor XIa inhibitionDonna L Pedicord, Dietmar Seiffert, Yuval Blat
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 30, 2005
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humansShaker A Mousa, Jeffrey M Bozarth, Dietmar Seiffert, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 9, 2007
Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonistYu Chen Barrett, William Ebling, Henry Pieniaszek, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 8, 2016
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in RabbitsXueping Zhou, Weizhen Wu, Lin Chu, et al.
Thrombosis Research|February 5, 2003
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancyJeffrey T Billheimer, Bokang He, Susan M Spitz, et al.
Clinical and Translational Science|September 24, 2021
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Joseph Luettgen, et al.
Platelets|July 3, 2023
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participantsSamira Merali, Zhaoqing Wang, Charles Frost, et al.
Pageof 5